Altamira Therapeutics to Host First Half 2025 Financial Results and Business Update Call on August 29, 2025

Arizona Tribune - Altamira Therapeutics to Host First Half 2025 Financial Results and Business Update Call on August 29, 2025

Altamira Therapeutics to Host First Half 2025 Financial Results and Business Update Call on August 29, 2025

HAMILTON, BERMUDA / ACCESS Newswire / August 26, 2025 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCQB:CYTOF), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that it will host its Half Year 2025 Financial Results and Business Update Call on Friday, August 29, 2025. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver prepared remarks.

Text size:

Event: Altamira Therapeutics First Half 2025 Financial Results and Business Update Call

Date: Friday, August 29, 2025

Time: 8:00 am ET

Access:

Toll Free: 888-506-0062
International: 973-528-0011
Participant Access Code: 427043

Webcast URL: https://www.webcaster4.com/Webcast/Page/2797/52765

Participants will be greeted by an operator and asked for the access code. If a caller does not have the code, they can reference the company name.

The call will be in listen-only mode.

A replay of the call will be available 30 minutes after the live event via the Investors section of the Altamira website at https://ir.altamiratherapeutics.com/.

Replay access:

Toll Free: 877-481-4010
International: 919-882-2331
Replay Passcode: 52765

Expiration: Friday, September 12, 2025

About Altamira Therapeutics

Altamira Therapeutics (OTCQB:CYTOF) is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (xPhore™ platform). The Company currently has two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. The versatile delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing. In addition, Altamira holds a 49% stake (with additional economic rights) in Altamira Medica AG, which holds its commercial-stage legacy asset Bentrio®, an OTC nasal spray for allergic rhinitis. Further, the Company is in the process of partnering / divesting its inner ear legacy assets. Founded in 2003, Altamira is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit: https://altamiratherapeutics.com/

Investor Contact

[email protected]

SOURCE: Altamira Therapeutics

View the original press release on ACCESS Newswire

H.Gonzales--AT

RBGPF	0.11%	70.77	$
BCC	-0.03%	78.75	$
CMSC	-0.09%	21.29	$
VOD	1%	16.04	$
RYCEF	-1.22%	20.5	$
BP	-0.45%	42.15	$
JRI	-0.4%	12.35	$
GSK	1.08%	50.82	$
RIO	-1.43%	103.3	$
BTI	-0.27%	56.13	$
CMSD	0%	21.18	$
RELX	0.66%	36.54	$
BCE	0.26%	23.46	$
AZN	-1.12%	162.7	$
NGG	-0.1%	79.35	$

Arizona Tribune - Altamira Therapeutics to Host First Half 2025 Financial Results and Business Update Call on August 29, 2025

Altamira Therapeutics to Host First Half 2025 Financial Results and Business Update Call on August 29, 2025

Featured

Malaysia's Sarawak eyes cloud seeding as haze worsens

Transitional Fashion Essentials for Autumn: Key Pieces from M&S and Joe Browns

Rescuers hunt for missing after deadly N.Cyprus ferry accident

Nepal recovers bodies but presses on for trapped tunnel workers